Molbio Diagnostics IPO: What Brokerages say: Buy or avoid?
Issue opens today at Rs 768-807 price band
The initial public offering (IPO) of Molbio Diagnostics, a Temasek and Motilal Oswal Private Equity-backed company, opened today with a price band of Rs 768-807 per share. The ₹939.70 crore IPO closes on Wednesday, with up to 50% reserved for Qualified Institutional Buyers (QIBs) and retail investors allowed to bid up to 35% of the net offer.
The company has reserved approximately 20,500 shares for its employees at a discount of ₹76 per share. Molbio Diagnostics, based in Goa, offers point-of-care diagnostics for 30 diseases, including tuberculosis, COVID-19, hepatitis, HIV, and HPV. The company's innovative 'Truenat' platform, a battery-operated polymerase chain reaction system, delivers rapid, accurate diagnoses in resource-limited settings.
With a strong competitive position and supportive R&D, patent portfolio, and global presence, Molbio Diagnostics appears to be a promising long-term investment opportunity.
Written by urgent.news from Hindu BusinessLine's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
